Highest-materiality recent filing
Ionis Q1 revenue up 87% to $246M; raises 2026 guidance; olezarsen sHTG peak sales view >$3B
Total revenue $246M (+87% YoY); GAAP operating loss $118M; non-GAAP loss $75M.
Ionis zilganersen meets primary endpoint in Alexander disease; PDUFA Sept 22, 2026
Primary endpoint met: gait speed stabilized vs control at Week 61 (LS mean diff 33.3%, p=0.041) in patients ≥5 years.
Ionis FY2025 total revenue $944M (+34% YoY); guides 2026 rev $800-825M, op loss $500-550M
FY2025 total revenue $944M (2024: $705M); Q4 revenue $203M.
TRYNGOLZA generated $105M in preliminary 2025 U.S. net product sales, outperforming expectations as first FDA-approved FCS treatment.
Bepirovirsen Phase 3 positive: primary endpoint met, functional cure rates superior to SOC
Over 1,800 patients enrolled in two Phase 3 studies (B-Well 1 & 2) across 29 countries.
Ionis closes $770M 0% convertible notes offering, repurchases $200M of 2026 notes
Issued $770M aggregate principal of 0.00% Convertible Senior Notes due 2030 (including full greenshoe), net proceeds ~$751.2M.
Ionis reports Phase 3 olezarsen results: 72% TG reduction, 85% fewer pancreatitis events
Primary endpoint met: up to 72% placebo-adjusted mean reduction in fasting triglycerides at 6 months, sustained through 12 months (p<0.001).
Ionis Q3 revenue $157M, up 17% YoY; raises FY 2025 guidance on TRYNGOLZA strength
TRYNGOLZA Q3 net sales $32M, ~70% QoQ increase; FY guidance raised to $85-95M.
Primary endpoint met: gait speed improved 33.3% vs control (p=0.0412) at week 61 in 50 mg cohort.
Olezarsen achieved 72% placebo-adjusted mean reduction in fasting triglycerides in Phase 3 CORE study (p<0.0001)
FDA approves Ionis' DAWNZERA (donidalorsen) for HAE prophylaxis in patients 12+
First and only RNA-targeted HAE medicine; self-administered every 4 or 8 weeks via autoinjector.
Ionis Q2 revenue doubles to $452M; raises FY 2025 guidance, TRYNGOLZA sales $19M
Q2 total revenue $452M (up from $225M); GAAP income from ops $140M vs loss $66M year ago.
Ionis announces positive Phase 3 Essence study of olezarsen in moderate hypertriglyceridemia
Primary endpoint met: placebo-adjusted 61% (80 mg) and 58% (50 mg) reduction in TG at 6 months (p<0.0001).
On June 12, 2025, the Company issued a press release announcing that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed Dr. Richard Geary Ph.D. in the role of executive vice president and chief development officer beginning in January 2026.
On June 12, 2025, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Richard Geary Ph.D., executive vice president and chief development officer, will retire effective January 2026.
Max materiality 0.90 · Median 0.80 · Most common event other_material